Skip to main content
. 2024 Oct 8;32(1):132–143. doi: 10.1007/s12282-024-01640-z

Fig. 2.

Fig. 2

Investigator-assessed PFS in patients with PIK3CA/AKT1/PTEN-altered tumors in a the Japan subgroup, and b the global CAPItello-291 population. The hazard ratio was estimated in the Japan subgroup using an unstratified Cox proportional hazards model, and in the global CAPItello-291 population using the Cox proportional hazards model stratified according to the presence or absence of liver metastases and previous CDK4/6 inhibitor use. Tick marks indicate censored data. b New England Journal of Medicine. Turner et al. [16]. Copyright © (2023) Massachusetts Medical Society. Reprinted with permission. AKT1 Akt serine/threonine kinase 1, CI confidence interval, NC not calculable, PFS progression-free survival, PIK3CA catalytic subunit of phosphatidylinositol-3-kinase, PTEN phosphatase and tensin homolog